Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Receivables (2018 - 2025)

AVITA Medical filings provide 8 years of Receivables readings, the most recent being $9.1 million for Q4 2025.

  • On a quarterly basis, Receivables fell 22.91% to $9.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.1 million, a 22.91% decrease, with the full-year FY2025 number at $9.1 million, down 22.91% from a year prior.
  • Receivables hit $9.1 million in Q4 2025 for AVITA Medical, up from $9.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $12.0 million in Q1 2025 to a low of $3.4 million in Q4 2021.
  • Median Receivables over the past 5 years was $6.6 million (2023), compared with a mean of $7.1 million.
  • Biggest five-year swings in Receivables: surged 204.4% in 2021 and later tumbled 42.97% in 2022.
  • AVITA Medical's Receivables stood at $3.4 million in 2021, then increased by 28.81% to $4.4 million in 2022, then surged by 74.35% to $7.7 million in 2023, then soared by 53.18% to $11.8 million in 2024, then dropped by 22.91% to $9.1 million in 2025.
  • The last three reported values for Receivables were $9.1 million (Q4 2025), $9.0 million (Q3 2025), and $11.3 million (Q2 2025) per Business Quant data.